OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF)

Clinical trials for OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF) explained in plain language.

Never miss a new study

Get alerted when new OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF) trials appear

Sign up with your email to follow new studies for OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Novartis tests new shot for weakened hearts

Disease control Completed

This early-stage study tested the safety and side effects of a new drug called XXB750 for people with chronic heart failure. It involved 27 participants who received either the drug or a placebo via injection. The main goal was to see how well the drug was tolerated and how it mo…

Matched conditions: OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF)

Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Feb 19, 2026 14:37 UTC

OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF)

Get alerted when new OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF) trials appear

Novartis tests new shot for weakened hearts